Interview conducted by Didier Testot Founder of LA BOURSE ET LA VIE TV Stanislas Veillet, CEO of Biophytis, reviews the first results of the SARA-INT Phase 2 clinical trial with Sarconeos (BIO101) in sarcopenia and looks forward to a Phase 3 development. Watch the interview on labourseetlavie.com Partager cet article Share on LinkedInShare on LinkedIn TweetShare on Twitter Share on FacebookShare on Facebook Pin itShare on Pinterest Share on WhatsAppShare on WhatsApp Post navigationPreviousPrevious post:AUGUST 2, 2021NextNext post:AUGUST 13, 2021